APP Pharma‘s Nafcillin for injection, which is indicated for the treatment of infections caused by penicillinase-producing staphylococci, is the generic version of GlaxoSmithKline (GSK) marketed drug Nallpen and Wyeth’s Unipen.
Fresenius Kabi Pharmaceuticals’ subsidiary APP Pharma expects to market Nafcillin in 1gram and 2gram single dose vials, and a 10gram pharmacy bulk package.
APP Pharma president and CEO John Ducker said the approval of APP’s Nafcillin provides clinicians with a new supplier of this commonly used anti-infective medication.